AKT1 and non-small cell lung carcinoma: This leads to enhanced inhibition of EGFR, MAPK and AKT phosphorylation and cell proliferation, with the result of reduced IC50 for gefitinib in proliferation assays of EGFR wild-type NSCLC cell lines.